Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of “Hold” from Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been given an average rating of “Hold” by the six ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.00.

Several analysts have recently weighed in on IVVD shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Thursday, February 26th. D. Boral Capital restated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Finally, Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th.

Invivyd Trading Up 1.8%

Shares of IVVD opened at $1.74 on Friday. Invivyd has a 12-month low of $0.46 and a 12-month high of $3.07. The firm has a market capitalization of $405.63 million, a P/E ratio of -3.70 and a beta of 0.61. The firm has a 50-day moving average price of $2.01 and a 200 day moving average price of $1.81.

Insider Buying and Selling

In other Invivyd news, CFO William E. Duke sold 20,964 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the transaction, the chief financial officer owned 107,717 shares of the company’s stock, valued at $170,192.86. This trade represents a 16.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Timothy Edward Lee sold 20,964 shares of Invivyd stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the sale, the insider owned 117,717 shares of the company’s stock, valued at approximately $185,992.86. This represents a 15.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 227,172 shares of company stock valued at $354,534 over the last three months. Company insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP grew its stake in shares of Invivyd by 85.0% in the third quarter. GSA Capital Partners LLP now owns 805,221 shares of the company’s stock valued at $886,000 after buying an additional 369,891 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Invivyd during the 2nd quarter valued at about $27,000. Eventide Asset Management LLC acquired a new position in Invivyd in the 4th quarter valued at about $14,349,000. Eversept Partners LP increased its stake in Invivyd by 4.5% during the fourth quarter. Eversept Partners LP now owns 2,140,130 shares of the company’s stock worth $5,286,000 after purchasing an additional 92,865 shares during the period. Finally, Perceptive Advisors LLC acquired a new stake in shares of Invivyd during the fourth quarter worth about $53,809,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.